Alzheimer's Treatment

Protecting Synapses in Adults: An Early Intervention for Alzheimer’s?

What do the developing brain and the Alzheimer’s brain have in common? Beth Stevens, Ph.D., a developmental neurologist, is investigating an important connection: the loss of synapses, where neurons connect with one another to transmit important signals.

Alzstream™ Webinar: Bringing Gamma Secretase Modulators to Trials

Friday, Sep. 16, 2016

Bringing Gamma Secretase Modulators to Trials: Steven Wagner, Ph.D.

Find out about the exciting progress being made with gamma secretase modulators, a potential drug therapy for Alzheimer’s, in this one-hour webinar. Steven Wagner, Ph.D., principal investigator at UC San Diego's Department of Neuroscience, talks to David Shenk, senior adviser, Cure Alzheimer's Fund, about how the modulators work and what’s being done to get them to human trials. This webinar was recorded at our annual Research Consortium meeting in San Diego.

Amyloid Screening and its Role in Alzheimer's Diagnosis

Dr. Rudy Tanzi talks to MD Magazine about recent developments in Alzheimer's research and the role that amyloid screening may play going forward. He also discusses best strategies for treatment.

Alzheimer's and Antidepressants: Dr. Rudy Tanzi Comments

Segment on Alzheimer's disease begins at 3:10.

Last week, many news stories broke about a recent study suggesting levels of amyloid, the sticky substance that builds up in the brain of Alzheimer's patients, may be lowered by the antidepressant Celexa. Dr. Rudy Tanzi, of Harvard Medical School/Massachusetts General Hospital and chair of Cure Alzheimer's Fund's Research Consortium, appeared on the CBS Morning Show to discuss the story.

Alzheimer's and Antidepressants: Rudy Tanzi, Ph.D. on CBS

Rudy Tanzi, Ph.D., appears on the CBS Morning Show to discuss a recent study about Alzheimer's and antidepressants.

The segment on Alzheimer's begins at 3:10.

Our Mission

An introduction to the problem of Alzheimer's and Cure Alzheimer's Fund's approach to solving it.

This video was originally shown at our 2013 Fall Symposium.

Promising Update on Efficacy and Safety of “Molecular Tweezers”

Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).

Your Alzheimer’s Questions Answered: Q&A with Rudy Tanzi

We collected your questions about Alzheimer's from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below!

Inside the Alzheimer's Lab: Rudy Tanzi, Ph.D.

Dr. Rudy Tanzi of Harvard Medical School/Mass General Hospital talks to David Shenk about his research into CD33 inhibitors, which show promise in curtailing the damaging brain inflammation that occurs in Alzheimer's disease.

Inside the Alzheimer's Lab: David Holtzman, M.D.

Dr. David Holtzman of Washington University in St. Louis explains his work on the tau protein in relation to Alzheimer's disease.